OROS Methylphenidate Long-Term Study in ADHD
Abstract
Once-daily osmotic controlled-release (OROS) methylphenidate (Concerta) in the treatment of 407 children, aged 6-13 years, with ADHD who were known MPH responders, was evaluated in a 24-month multicenter, open-label, nonrandomized study, and reported from the Massachusetts General Hospital, Boston.
DOI: https://doi.org/10.15844/pedneurbriefs-17-5-9 | Journal eISSN: 2166-6482
Language: English
Page range: 40 - 40
Published on: May 1, 2003
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services
Keywords:
© 2003 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.